Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Alkalinization by Urologists & Nephrologists (AlcalUN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03035812
Recruitment Status : Recruiting
First Posted : January 30, 2017
Last Update Posted : February 5, 2020
Sponsor:
Information provided by (Responsible Party):
Jean-Philippe Bertocchio, Club des Jeunes Néphrologues

Brief Summary:
Metabolic acidosis recovers a wide range of diseases in which an oral alkalinization could be useful. This therapeutic intervention has been said to increase extracellular volume leading to rising blood pressure. No prospective data has been published in clinical routine. Here, investigators propose to follow patients in which an oral alkalinization is indicated: blood pressure, body weight, and a clinical evaluation of the extracellular compartment will be performed at the beginning and during the follow-up of participants. The principal criterion of evaluation will be the variation in the extracellular compartment.

Condition or disease Intervention/treatment Phase
Metabolic Acidosis Nephrolithiasis Extracellular Alteration Blood Pressure Body Weight Drug: Alkali Phase 4

Detailed Description:

Metabolic acidosis recovers a wide range of diseases - chronic kidney diseases, nephrolithiasis, or others - in which an oral alkalinization could be useful. Oral alkalinization could be performed or by bicarbonate contained in alkaline-based waters or drug therapies or by citrate. This therapeutic intervention has been said to increase extracellular volume leading to rising blood pressure, especially due to the amount of daily sodium load. No prospective data has been published in clinical routine, studying its effects on extracellular volume nor the blood pressure control.

Here, investigators propose to follow patients in which an oral alkalinization is indicated: blood pressure, body weight, and a clinical evaluation of the extracellular compartment will be performed at the beginning and during the follow-up of participants. Initial recorded data will be: age, gender, prescription (indication, kind of alkali therapy, volume and duration), body weight, body length, a clinical appreciation of the extracellular compartment, blood pressure, comorbidities, drug therapy, blood and urine composition. The recorded follow-up will be: the adherence to treatment, body weight, body length, a clinical appreciation of the extracellular compartment, blood pressure, adverse events, blood and urine composition.

The principal criterion of evaluation will be the variation in the extracellular compartment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Clinical and biological evaluation before and after an oral alkalinization
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective Evaluation of Oral Alkalinization by Urologists and Nephrologists: Evolution of the Extracellular Compartment
Actual Study Start Date : February 1, 2017
Estimated Primary Completion Date : March 1, 2020
Estimated Study Completion Date : March 1, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Alkali
Patients in whom an oral alkalinization whatever the formulation
Drug: Alkali
Oral intake of alkali therapy whatever the formulation (alkali-based water, powder or pharmaceutics)
Other Names:
  • Bicarbonate
  • Citrate




Primary Outcome Measures :
  1. Extracellular compartment M3 [ Time Frame: At M3 (month 3) ]
    Evaluation of the extracellular compartment by a composite clinical outcome at M3 composed by: body weight (kg), blood pressure (in mmHg, systolic and diastolic), and the presence edema


Secondary Outcome Measures :
  1. Natremia (mM) [ Time Frame: At M3 (month 3) ]
    Evaluation of the impact of oral alkali therapy on natremia (mM)

  2. Urine output (l/d) [ Time Frame: At M3 (month 3) ]
    Evaluation of the impact of oral alkali therapy on urine output (l/d)

  3. Extracellular compartment M6 [ Time Frame: At M6 (month 6) ]
    Evaluation of the extracellular compartment by a composite clinical outcome at M6 composed by: body weight (kg), blood pressure (in mmHg, systolic and diastolic), and the presence edema

  4. Kalemia (mM) [ Time Frame: At M3 (month 3) ]
    Evaluation of the impact of oral alkali therapy on kalemia (mM)

  5. Blood chloride (mM) [ Time Frame: At M3 (month 3) ]
    Evaluation of the impact of oral alkali therapy on blood chloride (mM)

  6. Bicarbonatemia (mM) [ Time Frame: At M3 (month 3) ]
    Evaluation of the impact of oral alkali therapy on bicarbonatemia (mM)

  7. Proteinemia (g/l) [ Time Frame: At M3 (month 3) ]
    Evaluation of the impact of oral alkali therapy on proteinemia (mM)

  8. Albuminemia (g/l) [ Time Frame: At M3 (month 3) ]
    Evaluation of the impact of oral alkali therapy on albuminemia (mM)

  9. Creatininemia (microM) [ Time Frame: At M3 (month 3) ]
    Evaluation of the impact of oral alkali therapy on creatininemia (mM)

  10. Natriuresis (mmol/d) [ Time Frame: At M3 (month 3) ]
    Evaluation of the impact of oral alkali therapy on natriuresis (mmol/d)

  11. Urine chloride (mmol/d) [ Time Frame: At M3 (month 3) ]
    Evaluation of the impact of oral alkali therapy on urine chloride (mmol/d)

  12. Proteinuria (g/d) [ Time Frame: At M3 (month 3) ]
    Evaluation of the impact of oral alkali therapy on proteinuria (g/d)

  13. Creatinuria (mmol/d) [ Time Frame: At M3 (month 3) ]
    Evaluation of the impact of oral alkali therapy on creatinuria (mmol/d)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • > or = to 18 years old
  • in whom an oral alkalinization is indicated

Exclusion Criteria:

  • if the patient mentions its opposition to his/her enrollment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03035812


Contacts
Layout table for location contacts
Contact: Julie Beaume, MD 33483162344 etude.alcalun@gmail.com
Contact: Jean-Philippe Bertocchio, MD, PhD 33156092866 jpbertocchio@gmail.com

Locations
Show Show 18 study locations
Sponsors and Collaborators
Jean-Philippe Bertocchio
Investigators
Layout table for investigator information
Principal Investigator: Julie Beaume, MD Club des Jeunes Néphrologues
Layout table for additonal information
Responsible Party: Jean-Philippe Bertocchio, President, Investigator, Club des Jeunes Néphrologues
ClinicalTrials.gov Identifier: NCT03035812    
Other Study ID Numbers: AlcalUN
First Posted: January 30, 2017    Key Record Dates
Last Update Posted: February 5, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Jean-Philippe Bertocchio, Club des Jeunes Néphrologues:
Bicarbonate
Additional relevant MeSH terms:
Layout table for MeSH terms
Nephrolithiasis
Kidney Calculi
Acidosis
Body Weight
Signs and Symptoms
Acid-Base Imbalance
Metabolic Diseases
Kidney Diseases
Urologic Diseases
Urolithiasis
Urinary Calculi
Calculi
Pathological Conditions, Anatomical